论文部分内容阅读
血脂异常是心血管系统最重要的危险因素之一。大量临床研究证实,应用他汀类药物降低胆固醇水平可以降低动脉粥样硬化性心血管疾病的发生率与致死致残率。然而近年研究显示,血脂异常患者即使经过大剂量他汀强化降胆固醇治疗后仍面临很高的心血管剩留风险[1],而在2型糖尿病、肥胖、代谢综合征和(或)心血管病患者中,甘油三酯(TG)升高和高密度脂蛋白胆固醇(HDL-C)降低是构成心血管剩留风险的主要血脂异常表型[2]。因此,在关注高胆固醇血症的危害性以及强调他汀类药物在心血管疾病防治中基石
Dyslipidemia is one of the most important risk factors of the cardiovascular system. A large number of clinical studies have confirmed that the use of statins to reduce cholesterol levels can reduce the incidence of atherosclerotic cardiovascular disease and lethality. However, recent studies have shown that patients with dyslipidemia are still at high risk of cardiovascular remodeling even after high-dose statin-fortified cholesterol-lowering treatment [1], whereas in patients with type 2 diabetes, obesity, metabolic syndrome and / or cardiovascular disease Among the patients, elevated triglycerides (TG) and decreased high-density lipoprotein cholesterol (HDL-C) are the major dyslipidemic phenotypes that contribute to cardiovascular residual risk [2]. Therefore, focusing on the dangers of hypercholesterolemia and emphasizing the cornerstone of statins in the prevention and treatment of cardiovascular disease